Las Vegas, NV -- (SBWIRE) -- 12/05/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: ChemoCentryx Inc (NASDAQ:CCXI), Pacific Ethanol Inc (NASDAQ:PEIX), Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT)
ChemoCentryx Inc (NASDAQ:CCXI) managed to keep its gain at 2.79% on above-normal volume of 1.84M shares. The stock settled at $5.16 after floating in a range of $5.11 to $5.38. Its latest price has reached market capitalization of $221.19 million. Its 52-week range has been $4.57 to $14.96. ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation.
For How Long CCXI will fight for Profitability? Read This Trend Analysis report
Pacific Ethanol Inc (NASDAQ:PEIX) traded up on a volume of 1.82 million, higher than its standard daily volume. Shares have gained 14.25% to $4.29. Over the last twelve months, the stock has lost-10.62% and faced a worst price of $2.33. Pacific Ethanol, Inc. (Pacific Ethanol) is a marketer and producer of low-carbon renewable fuels in the Western United States. Pacific Ethanol markets all the ethanol produced by four ethanol production facilities located in California, Idaho and Oregon, or the Pacific Ethanol Plants, all the ethanol produced by three other ethanol producers in the Western United States and ethanol purchased from other third-party suppliers throughout the United States.
For How Long PEIX’s Gloss will Attract Investors? Find out via this report
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) settled 5.35% higher at $1.97 on above-normal volume of 1.81M shares during the last trading day. The stock has its 12-month high at $3.65 and 52-week low price was $0.41. It traded in a range of $1.83 to $2.02 during the last trading day. Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011, the Company had two drugs in development: CPP-109 and CPP-115. of December 31, 2011.
Why Should Investors Buy CPRX After the Recent Fall? Just Go Here and Find Out
In the last trading session, Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) was up on low volume, trading at a volume of 1.80M versus its average daily volume of 6.29 million shares. At $6.31, the stock has attained market capitalization of 34.36 million. Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics) is engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue. As of April 30, 2011, the Company is developing Oxycyte, a systemic perfluorcarbon (PFC), product. It has developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. In addition,.
Will OXBT Continue To Move Higher? Find Out Here
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)